{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:09Z","timestamp":1787020869784,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T00:00:00Z","timestamp":1451433600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although metformin, a first-line drug for treating diabetes, may play an important role in inhibition of epithelial ovarian cancer cell growth and cancer stem cells (CSCs), metformin at low dose showed less effect on the proliferation of ovarian cancer cells. In this study, we evaluated the effect of metformin at low dose on ovarian CSCs in order to understand the molecular mechanisms underlying.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The inhibitory effects of metformin at los dose on proliferation and population of ovarian cancer cells including SKOV3 and A2780 were assessed by cell proliferation assay and flow cytometry. Quantitative real-time PCR assay on expression of Bcl-2, Survivin and Bax was performed to determine the effect of metformin at low dose on epithelial-mesenchymal transition (EMT) of cancer cells and CSCs. Tumor sphere formation assay was also performed to evaluate the effect of metformin on spheres forming ability of CSCs. The therapeutic efficacy and the anti-CSC effects of metformin at low dose were investigated by using both SKOV3 cells and primary tumor xenografts. In addition, the CSC frequency and EMT in tumor xenograft models were also assessed by flow cytometry and quantitative real-time PCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Metformin at low dose did not affect the proliferation of ovarian cancer cells. However, it inhibited population of CD44\n                      <jats:sup>+<\/jats:sup>\n                      CD117\n                      <jats:sup>+<\/jats:sup>\n                      selectively, neither CD133\n                      <jats:sup>+<\/jats:sup>\n                      nor ALDH\n                      <jats:sup>+<\/jats:sup>\n                      cells. It suppressed expression of snail2, twist and vimentin significantly in cancer cells and CD44\n                      <jats:sup>+<\/jats:sup>\n                      CD117\n                      <jats:sup>+<\/jats:sup>\n                      CSCs\n                      <jats:italic>in vitro<\/jats:italic>\n                      . Low dose of metformin reduced survivin expression in CSCs. Low concentrations of metformin inhibited the secondary and the tertiary tumor sphere formation, decreased SKOV3 and primary ovarian tumor xenograft growth, enhanced the anticancer effect of cisplatin, and lowered the proportion of CD44\n                      <jats:sup>+<\/jats:sup>\n                      CD117\n                      <jats:sup>+<\/jats:sup>\n                      CSCs in the xenograft tissue. Metformin was also associated with a reduction of snail2, twist, and vimentin in CD44\n                      <jats:sup>+<\/jats:sup>\n                      CD117\n                      <jats:sup>+<\/jats:sup>\n                      ovarian CSCs\n                      <jats:italic>in vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our results implicate that metformin at low dose inhibits selectively CD44\n                      <jats:sup>+<\/jats:sup>\n                      CD117\n                      <jats:sup>+<\/jats:sup>\n                      ovarian CSCs through inhibition of EMT and potentiates the effect of cisplatin.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-015-0249-0","type":"journal-article","created":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T13:09:55Z","timestamp":1451480995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Inhibitory effects of metformin at low concentration on epithelial\u2013mesenchymal transition of CD44+CD117+ ovarian cancer stem cells"],"prefix":"10.1186","volume":"6","author":[{"given":"Rongrong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guishan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,30]]},"reference":[{"key":"249_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3322\/caac.20121","volume":"61","author":"R Siegel","year":"2011","unstructured":"Siegel R, Ward E, Brawley O. Cancer statistics, 2011. CA Cancer J Clin. 2011;61:212\u201336.","journal-title":"CA Cancer J Clin."},{"key":"249_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415\u201328.","journal-title":"Nat Rev Cancer."},{"key":"249_CR3","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1200\/JCO.2008.17.7436","volume":"26","author":"BM Boman","year":"2008","unstructured":"Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol. 2008;26:2795\u20139.","journal-title":"J Clin Oncol."},{"key":"249_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2012.02.002","volume":"322","author":"D Burgos-Ojeda","year":"2012","unstructured":"Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett. 2012;322:1\u20137.","journal-title":"Cancer Lett."},{"key":"249_CR5","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1158\/0008-5472.CAN-10-3175","volume":"71","author":"IA Silva","year":"2011","unstructured":"Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011;71:3991\u20134001.","journal-title":"Cancer Res."},{"issue":"2","key":"249_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ygyno.2012.07.115","volume":"127","author":"JJ Shank","year":"2012","unstructured":"Shank JJ, Yang K, Ghannam J. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol. 2012;127(2):390\u20137.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"249_CR7","doi-asserted-by":"publisher","first-page":"e10277","DOI":"10.1371\/journal.pone.0010277","volume":"5","author":"S Deng","year":"2010","unstructured":"Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One. 2010;5(4):e10277.","journal-title":"PLoS One"},{"issue":"11","key":"249_CR8","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","volume":"68","author":"S Zhang","year":"2008","unstructured":"Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68(11):4311\u201320.","journal-title":"Cancer Res"},{"issue":"1","key":"249_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1757-2215-6-50","volume":"6","author":"D Chen","year":"2013","unstructured":"Chen D, Zhang Y, Wang J. MicroRNA-200c over expression inhibits tumor igenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J Ovarian Res. 2013;6(1):50.","journal-title":"J Ovarian Res"},{"key":"249_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1525-1438.2007.01056.x","volume":"18","author":"G Ferrandina","year":"2008","unstructured":"Ferrandina G, Bonanno G, Pierelli L. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer. 2008;18:506\u201314.","journal-title":"Int J Gynecol Cancer."},{"issue":"12","key":"249_CR11","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/stem.236","volume":"27","author":"MD Curley","year":"2009","unstructured":"Curley MD, Therrien VA, Cummings CL. CD133 expression defines atumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;27(12):2875\u201383.","journal-title":"Stem Cells"},{"key":"249_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2008.04.008","volume":"110","author":"WH Gotlieb","year":"2008","unstructured":"Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN. In vitro metformin antineoplasticactivity in epithelial ovarian cancer. Gynecol Oncol. 2008;110:246\u201350.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"249_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrm1835","volume":"7","author":"JP Thiery","year":"2006","unstructured":"Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"249_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704\u201315.","journal-title":"Cell"},{"issue":"6","key":"249_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ceb.2003.10.006","volume":"15","author":"JP Thiery","year":"2003","unstructured":"Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15(6):740\u20136.","journal-title":"Curr Opin Cell Biol"},{"key":"249_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/0008-5472.CAN-07-2017","volume":"68","author":"D Sarrio","year":"2008","unstructured":"Sarrio D, Rodriguez-Piniella SM, Harrison D. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68:989\u201397.","journal-title":"Cancer Res."},{"key":"249_CR17","doi-asserted-by":"publisher","first-page":"e2888","DOI":"10.1371\/journal.pone.0002888","volume":"3","author":"AP Morel","year":"2008","unstructured":"Morel AP, Lievre M, Thomas C. Generation of breast cancerstem cells through epithelial-mesenchymal transition. PLoS One. 2008;3:e2888.","journal-title":"PLoS One."},{"key":"249_CR18","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.4161\/cc.9.18.13131","volume":"9","author":"A Vazquez-Martin","year":"2010","unstructured":"Vazquez-Martin A, Oliveras-Ferraros C, Cufi S. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle. 2010;9:3807\u201314.","journal-title":"Cell Cycle."},{"key":"249_CR19","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","volume":"69","author":"HA Hirsch","year":"2009","unstructured":"Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507\u201311.","journal-title":"Cancer Res."},{"issue":"9","key":"249_CR20","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1002\/stem.154","volume":"27","author":"NK Kurrey","year":"2009","unstructured":"Kurrey NK, Jalgaonkar SP, Joglekar AV. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 2009;27(9):2059\u201368.","journal-title":"Stem Cells"},{"issue":"5","key":"249_CR21","doi-asserted-by":"publisher","first-page":"e63969","DOI":"10.1371\/journal.pone.0063969","volume":"8","author":"S Gou","year":"2013","unstructured":"Gou S, Cui P, Li X. Low concentrations of metformin selectively inhibit CD133+cell proliferation in pancreatic cancer and have anticancer action. PLoS One. 2013;8(5):e63969.","journal-title":"PLoS One"},{"key":"249_CR22","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1038\/srep05810","volume":"4","author":"T Hu","year":"2014","unstructured":"Hu T, Chung YM, Guan M. Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. Sci Rep. 2014;4:5810.","journal-title":"Sci Rep."},{"key":"249_CR23","first-page":"889","volume":"6","author":"F Tomao","year":"2013","unstructured":"Tomao F, Papa A, Rossi L. Current status of bevacizumab in advancedovarian cancer. Onco Targets Ther. 2013;6:889\u201399.","journal-title":"Onco Targets Ther."},{"key":"249_CR24","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/j.1349-7006.2008.00914.x","volume":"99","author":"H Ishii","year":"2008","unstructured":"Ishii H, Iwatsuki M, Ieta K. Cancer stem cells and chemoradiation resistance. Cancer Sci. 2008;99:1871\u20137.","journal-title":"Cancer Sci."},{"key":"249_CR25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra061808","volume":"355","author":"CT Jordan","year":"2006","unstructured":"Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253\u201361.","journal-title":"N Engl J Med."},{"issue":"5","key":"249_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1593\/neo.11148","volume":"13","author":"R Rattan","year":"2011","unstructured":"Rattan R, Graham RP, Maguire JL. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011;13(5):483\u201391.","journal-title":"Neoplasia"},{"issue":"43","key":"249_CR27","doi-asserted-by":"publisher","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","volume":"109","author":"SM McAuliffe","year":"2012","unstructured":"McAuliffe SM, Morgan SL, Wyant GA. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A. 2012;109(43):E2939\u201348.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"249_CR28","first-page":"667","volume":"6","author":"J Jiao","year":"2013","unstructured":"Jiao J, Huang L, Ye F. Cyclin D1 affects epithelial-mesenchymal transition in epithelial ovarian cancer stem cell-like cells. Onco Targets Ther. 2013;6:667\u201377.","journal-title":"Onco Targets Ther."},{"issue":"1","key":"249_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/onc.2012.33","volume":"32","author":"G Yin","year":"2013","unstructured":"Yin G, Alvero AB, Craveiro V. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene. 2013;32(1):39\u201349.","journal-title":"Oncogene"},{"issue":"20","key":"249_CR30","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1038\/onc.2011.429","volume":"31","author":"L Cao","year":"2012","unstructured":"Cao L, Shao M, Schilder J. Tissue transglutaminase links TGF-\u03b2, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012;31(20):2521\u201334.","journal-title":"Oncogene"},{"key":"249_CR31","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1158\/1535-7163.MCT-12-0463","volume":"11","author":"DM Cittelly","year":"2012","unstructured":"Cittelly DM, Dimitrova I, Howe EN. Restoration of miR-200c toovarian cancer reduces tumor burden and increases sensitivity topaclitaxel. Mol Cancer Ther. 2012;11:2556\u201365.","journal-title":"Mol Cancer Ther."},{"key":"249_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2131","volume":"7","author":"H Peinado","year":"2007","unstructured":"Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumor progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415\u201328.","journal-title":"Nat Rev Cancer."},{"key":"249_CR33","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war oncancer. Oncogene. 2010;29:4741\u201351.","journal-title":"Oncogene."},{"issue":"6","key":"249_CR34","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/cam4.115","volume":"2","author":"V Craveiro","year":"2013","unstructured":"Craveiro V, Yang-Hartwich Y, Holmberg JC. Phenotypic modifications in ovarian cancer stem cells following paclitaxel treatment. Cancer Med. 2013;2(6):751\u201362.","journal-title":"Cancer Med"},{"key":"249_CR35","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2119\/molmed.2012.00075","volume":"18","author":"H Jiang","year":"2012","unstructured":"Jiang H, Lin X, Liu Y. Transformation of epithelial ovarian cancer stem like cells into mesenchymal lineage via EMT results in cellular heterogeneity and supports tumor engraftment. Mol Med. 2012;18:1197\u2013208.","journal-title":"Mol Med."},{"key":"249_CR36","doi-asserted-by":"publisher","first-page":"e714","DOI":"10.1038\/cddis.2013.244","volume":"4","author":"J Lee","year":"2013","unstructured":"Lee J, Choi JH, Joo CK. TGF-\u03b21 regulates cell fate during epithelial-mesenchymal transition by upregulating Survivin. Cell Death Dis. 2013;4:e714.","journal-title":"Cell Death Dis."},{"issue":"4","key":"249_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/cpr.12043","volume":"46","author":"Z Dong","year":"2013","unstructured":"Dong Z, Yang L, Lai D. KLF5 strengthens drug resistance of ovarian cancer stem-like cells by regulating Survivin expression. Cell Proliferat. 2013;46(4):425\u201335.","journal-title":"Cell Proliferat"},{"key":"249_CR38","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ygyno.2011.02.021","volume":"121","author":"A Yasmeen","year":"2011","unstructured":"Yasmeen A, Beauchamp MC, Piura E. Induction of apoptosis bymetformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol. 2011;121:492\u20138.","journal-title":"Gynecol Oncol."}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-015-0249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-015-0249-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-015-0249-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-015-0249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T04:00:58Z","timestamp":1653969658000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-015-0249-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1186\/s13287-015-0249-0","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"16 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"262"}}